Overexpression of MiR-210 is Associated with SDH-related Pheochromocytomas, Paragangliomas, and Gastrointestinal Stromal Tumours
Overview
Oncology
Authors
Affiliations
miR-210 is a key regulator of response to hypoxia. Pheochromocytomas (PCs) and paragangliomas (PGLs) with germline SDHx or VHL mutations have pseudohypoxic gene expression signatures. We hypothesised that PC/PGLs containing SDHx or VHL mutations, and succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumours (GISTs), would overexpress miR-210 relative to non-SDH or -VHL-mutated counterparts. miR-210 was analysed by quantitative PCR in i) 39 PC/PGLs, according to genotype (one SDHA, five SDHB, seven VHL, three NF1, seven RET, 15 sporadic, one unknown) and pathology (18 benign, eight atypical, 11 malignant, two unknown); ii) 18 GISTs, according to SDHB immunoreactivity (nine SDH-deficient and nine SDH-proficient) and iii) two novel SDHB-mutant neurosphere cell lines. miR-210 was higher in SDHx- or VHL-mutated PC/PGLs (7.6-fold) compared with tumours without SDHx or VHL mutations (P=0.0016). miR-210 was higher in malignant than in unequivocally benign PC/PGLs (P=0.05), but significance was lost when benign and atypical tumours were combined (P=0.08). In multivariate analysis, elevated miR-210 was significantly associated with SDHx or VHL mutation, but not with malignancy. In GISTs, miR-210 was higher in SDH-deficient (median 2.58) compared with SDH-proficient tumours (median 0.60; P=0.0078). miR-210 was higher in patient-derived neurosphere cell lines containing SDHB mutations (6.5-fold increase) compared with normal controls, in normoxic conditions (P<0.01). Furthermore, siRNA-knockdown of SDHB in HEK293 cells increased miR-210 by 2.7-fold (P=0.001) under normoxia. Overall, our results suggest that SDH deficiency in PC, PGL and GISTs induces miR-210 expression and substantiates the role of aberrant hypoxic-type cellular responses in the development of these tumours.
[Advance in HIF expression and immune microenvironment in pseudohypoxic HNPGL].
Zhang B, Lou Z, Wang J, Hu Y, Chen Z Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2024; 38(9):823-829.
PMID: 39193740 PMC: 11839587. DOI: 10.13201/j.issn.2096-7993.2024.09.009.
Hypoxia signaling pathway: A central mediator in endocrine tumors.
Watts D, Jaykar M, Bechmann N, Wielockx B Front Endocrinol (Lausanne). 2023; 13:1103075.
PMID: 36699028 PMC: 9868855. DOI: 10.3389/fendo.2022.1103075.
Manso J, Bertazza L, Barollo S, Mondin A, Censi S, Carducci S Int J Mol Sci. 2022; 23(5).
PMID: 35269556 PMC: 8910416. DOI: 10.3390/ijms23052413.
Potential Biomarkers of Metastasizing Paragangliomas and Pheochromocytomas.
Snezhkina A, Pavlov V, Dmitriev A, Melnikova N, Kudryavtseva A Life (Basel). 2021; 11(11).
PMID: 34833055 PMC: 8619623. DOI: 10.3390/life11111179.
Tsoli M, Daskalakis K, Kassi E, Kaltsas G, Tsolakis A Biology (Basel). 2021; 10(7).
PMID: 34201922 PMC: 8301201. DOI: 10.3390/biology10070580.